View Item 

Show simple item record

Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C
dc.contributor.authorFontana, Robert Johnen_US
dc.contributor.authorKronfol, Ziad A.en_US
dc.contributor.authorLindsay, Karen L.en_US
dc.contributor.authorBieliauskas, Linas A.en_US
dc.contributor.authorPadmanabhan, Lathaen_US
dc.contributor.authorBack-Madruga, Carlaen_US
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.contributor.authorStoddard, Anne M.en_US
dc.date.accessioned2010-06-01T21:55:09Z
dc.date.available2010-06-01T21:55:09Z
dc.date.issued2008-11en_US
dc.identifier.citationFontana, Robert J.; Kronfol, Ziad; Lindsay, Karen L.; Bieliauskas, Linas A.; Padmanabhan, Latha; Back-Madruga, Carla; Lok, Anna S.F.; Stoddard, Anne M. (2008). "Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C." The American Journal of Gastroenterology 103(11): 2766-2775. <http://hdl.handle.net/2027.42/74953>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74953
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18721241&dopt=citationen_US
dc.format.extent143199 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2008 American College of Gastroenterology/Blackwell Publishingen_US
dc.titleChanges in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis Cen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Psychiatry, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumPsychology Service, Veterans Affairs Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDivision of Gastroenterologyen_US
dc.contributor.affiliationotherDivision of Gastrointestinal and Liver Diseasesen_US
dc.contributor.affiliationotherDepartment of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, Californiaen_US
dc.contributor.affiliationotherNew England Research Institutes, Watertown, Massachusettsen_US
dc.identifier.pmid18721241en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74953/1/j.1572-0241.2008.02106.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2008.02106.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceKronfol Z. Immune dysregulation in major depression: A critical review of existing evidence. Int J Neuropsychopharmacol 2002; 5: 333 – 43.en_US
dc.identifier.citedreferenceFontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18: 107 – 16.en_US
dc.identifier.citedreferenceLee SS, Peltekian K, Krajdens M, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40kD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397 – 408.en_US
dc.identifier.citedreferenceFried MW, Russo MA. Side effects of antiviral therapy for hepatitis C. Gastroenterology 2003; 124: 1711 – 9.en_US
dc.identifier.citedreferenceFontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during peginterferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007; 45: 1154 – 63.en_US
dc.identifier.citedreferenceHilsabeck RC, Hassanein TI, Carlson MD, et al. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. JINS 2003; 9: 847 – 54.en_US
dc.identifier.citedreferenceGleason OC, Yaters WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63: 194 – 8.en_US
dc.identifier.citedreferenceHauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942 – 7.en_US
dc.identifier.citedreferenceRaison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163 – 74.en_US
dc.identifier.citedreferenceMusselman DL, Lawson DH, Fumnick JF, et al. Paroxetine for the prevention of depression induced by high dose interferon-alfa. N Engl J Med 2001; 344: 961 – 6.en_US
dc.identifier.citedreferenceConstant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: Evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005; 66: 1050 – 7.en_US
dc.identifier.citedreferencePariante CM, Landau S, Carpiniello B. Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med 2002; 347: 148 – 9.en_US
dc.identifier.citedreferenceRaison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 2005; 66: 41 – 8.en_US
dc.identifier.citedreferenceCapuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon alpha with the development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342 – 5.en_US
dc.identifier.citedreferenceWeissenborn K, Ennen JC, Bokemeyer M, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006; 55: 1624 – 30.en_US
dc.identifier.citedreferenceBonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-a-based immunotherapy are related to interferon-a-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86 – 90.en_US
dc.identifier.citedreferenceCai W, Khaoustove VI, Xie Q, et al. Interferon-a-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005; 42: 880 – 7.en_US
dc.identifier.citedreferenceShifffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126: 1015 – 23.en_US
dc.identifier.citedreferenceLee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C trial: Pegylated interferon as a maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472 – 92.en_US
dc.identifier.citedreferenceShiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103 – 12.en_US
dc.identifier.citedreferenceWittchen HU. Reliability and validity studies of the WHO Composite International Diagnostic Interview: A critical review. J Psychiatr Res 1994; 28: 57 – 84.en_US
dc.identifier.citedreferenceBeck AT, Steer RA, Brown GK. BDI-II manual. The psychological corporation. San Antonio, TX: Harcourt Brace and Company, 1996.en_US
dc.identifier.citedreferenceSkinner HA, Sheu WJ. Reliability of alcohol use indices: The lifetime drinking history and the MAST. J Stud Alcohol 1982; 43: 1157 – 70.en_US
dc.identifier.citedreferenceFontana RJ, Bieliauskas LA, Back-Madruga C, et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005; 43: 614 – 22.en_US
dc.identifier.citedreferenceMalaguarnera M, DiFazio I, Restuccia S, et al. Interferon-alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93 – 7.en_US
dc.identifier.citedreferenceMistler LA, Brunette MF, Marsh BJ, et al. Hepatitis C treatment for people with severe mental illness. Psychosomatics 2006; 47: 93 – 107.en_US
dc.identifier.citedreferenceWhitley RJ, Meikle AW, Watts NB. Endocrinology, Part VI: Adrenocortical steroids. In: Burtis CA, Ashwood ER, eds. Textbook of clinical chemistry, 2nd Ed. Philadelphia, PA: WB Saunders, 1994: 1822 – 5.en_US
dc.identifier.citedreferenceXiao R, Beck O, Hjerndahl P. On the accurate measurement of serotonin in whole blood. Scand J Clin Lab Invest 1998; 58: 505 – 10.en_US
dc.identifier.citedreferenceSchaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with hepatitis C. J Hepatol 2005; 42: 793 – 8.en_US
dc.identifier.citedreferenceDan AA, Martin LM, Crone C, et al. Depression, anemia, and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 498.en_US
dc.identifier.citedreferenceRutledge T, Reis SE, Olson MB, et al. Depression severity and reported treatment history in the prediction of cardiac risk in women with suspected myocardial ischemia. Arch Gen Psychiatry 2006; 63: 874 – 80.en_US
dc.identifier.citedreferenceGrothe KB, Dutton GR, Jones GN, et al. Validation of the Beck Depression Inventory-II in a low-income African American sample of medical outpatients. Psychol Assess 2005; 17: 110 – 4.en_US
dc.identifier.citedreferenceDieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104 – 12.en_US
dc.identifier.citedreferenceGolden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: Prevalence, detection, and risk factors. Gen Hosp Psychiatry 2005; 27: 431 – 8.en_US
dc.identifier.citedreferenceCapuron L, Raynaud A. Prediction of the depressive effects of interferon-alfa therapy by the patient's initial affective state. N Engl J Med 1999; 340: 1370en_US
dc.identifier.citedreferenceRasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40 kD) (Pegasys) improves HR-QOL outcomes compared with unmodified interferon-2a in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341 – 9.en_US
dc.identifier.citedreferenceKraus MR, Schafer A, Csef H, et al. Compliance with therapy in patients with chronic hepatitis C. Dig Dis Sci 2001; 46: 260 – 5.en_US
dc.identifier.citedreferenceLoftis JM, Socherman RE, Howell CD, et al. Association of interferon-alpha induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004; 365: 87 – 91.en_US
dc.identifier.citedreferenceRaison CL, Pariante CM, Capuron L, et al. The association of fatigue with poor virologic response in patients receiving interferon-alpha plus ribavirin for the treatment of hepatitis C [abstract]. Hepatology 2005; 44: 1216.en_US
dc.identifier.citedreferenceRaison CL, Broadwell SD, Barisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 23 – 7.en_US
dc.identifier.citedreferenceMaddock C, Landau S, Barry K, et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: Effects on virologic response. Mol Psychiatry 2005; 10: 332 – 3.en_US
dc.identifier.citedreferenceCastera L, Constant A, Henry C, et al. Impact of adherence and sustained virologic response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 1223 – 30.en_US
dc.identifier.citedreferenceMuller H, Hiemke C, Hammes E, et al. Sub-acute effects of interferon-alpha 2 on ACTH, cortisol, growth hormone and prolactin in humans. Psychoneuroendocrinology 1992; 17: 459 – 65.en_US
dc.identifier.citedreferencePariante CM, Miller AH. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 394 – 404.en_US
dc.identifier.citedreferenceLopez JF, Chalmers DT, Little KY, et al. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid reception in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry 1998; 43: 547 – 73.en_US
dc.identifier.citedreferenceMaes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatr Scand 2004; 109: 126 – 31.en_US
dc.identifier.citedreferenceSchlaak JF, Trippler M, Erim Y, et al. Identification of candidate genes that mediate depressive side effects of pegylated IFN-alpha 2a in patients with chronic hepatitis C [abstract]. Hepatology 2006; 44: 331.en_US
dc.identifier.citedreferenceGladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: Potential for studying psychiatric disorders. Prog Neuropsychpharmacol Biol Psychiatry 2004; 28: 559 – 76.en_US
dc.identifier.citedreferenceYoshida K, Alagbe O, Wang X, et al. Promoter polymorphisms of the interferon-alpha receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: Preliminary findings. Neuropsychobiology 2005; 52: 55 – 61.en_US
dc.identifier.citedreferenceWichers MC, Koek GH, Robaeys G, et al. IDO and interferon-a-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538 – 44.en_US
dc.identifier.citedreferenceKraus MR, Al-Taie O, Schefer A, et al. Serotonin-1A receptor gene ( HTR1A ) variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007; 132: 1279 – 86.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2008.02106.x.pdf
Size:
139.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.